Fundraising FoxInvirsa Inc.
Columbus, US · Founded 2016 · Delaware corporation · 5 known investors
Find your way into Invirsa Inc.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Emma Off to introduce you to Rachael Wingo
You →Emma · together at Invirsa Inc. →Rachael
Sign up to find every way you can get introduced to Invirsa Inc.
- Your email: who you already know at Invirsa Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Invirsa Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
Founders & leadership
Invirsa Inc. was founded in 2016 by Robert Shalwitz.
Board
Investors · 5
How we know: CincyTech's portfolio page · board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: JobsOhio Ventures's portfolio page · Not right? Tell us
How we know: Jumpstart Ventures's portfolio page · press coverage · Not right? Tell us
How we know: Ohio Innovation Fund's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: board seat on SEC Form D · funding news · press coverage · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 4 rounds · 2020–2025
▶$2.9MraisedAug 2025 · 14 investors · PharmaceuticalsRule 506(b)
- Rachael WingoExecutive Officer
- Wayne EmbreeDirector
- Tim WillisDirector
- Robert ShalwitzExecutive Officer, Director
- Faith VoinovichDirector
- Offering amount
- $2.9M
- Amount sold
- $2.9M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1000KraisedNov 2023 · 1 investors · PharmaceuticalsRule 506(b)
- Wayne EmbreeDirector
- Samuel LeeDirector
- Tim WillisDirector
- Faith VoinovichDirector
- Robert ShalwitzExecutive Officer, Director
- Offering amount
- $1000K
- Amount sold
- $1000K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedDec 2022 · 8 investors · PharmaceuticalsRule 506(b)
- Robert ShalwitzExecutive Officer, Director
- Faith VoinovichDirector
- Wayne EmbreeDirector
- Samuel LeeDirector
- Tim WillisDirector
- Offering amount
- $7.7M
- Amount sold
- $6M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.2KraisedDec 2020 · 1 investors · PharmaceuticalsRule 506(b)
- Faith VoinovichDirector
- Bethany GeorgeDirector
- Michael VenerableDirector
- Robert ShalwitzExecutive Officer, Director
- Tim WillisDirector
- Offering amount
- $40.2K
- Amount sold
- $40.2K
- Minimum investment
- $40.2K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Invirsa Inc. do?
- Invirsa is a clinical-stage biopharmaceutical company developing DNA damage response therapeutics, with lead compound INV-102 in development for ocular conditions including sulfur mustard gas injury and diabetic dry eye disease.
- Who founded Invirsa Inc.?
- Invirsa Inc. was founded by Robert Shalwitz in 2016.
- Who are Invirsa Inc.'s investors?
- Invirsa Inc.'s investors include CincyTech, JobsOhio Ventures, Jumpstart Ventures, Ohio Innovation Fund, Rev1 Ventures.
- How much funding has Invirsa Inc. raised?
- Invirsa Inc. has disclosed $9.9M raised across 4 rounds.
- Where is Invirsa Inc. headquartered?
- Invirsa Inc. is headquartered in Columbus, US.